Does atorvastatin increase serum creatinine and decrease glomerular filtration rate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Atorvastatin Increase Creatinine and Drop GFR?

No, atorvastatin does not increase creatinine or decrease GFR in clinical practice—in fact, the evidence demonstrates that atorvastatin improves kidney function over time in a dose-dependent manner.

Key Evidence from FDA Labeling and Guidelines

The FDA label for atorvastatin explicitly states that atorvastatin has minimal renal excretion (<2%), making it the least dependent on kidney function among statins 1. The 2016 American Heart Association guidelines confirm this, noting that atorvastatin has the lowest renal excretion of all statins, which minimizes concerns about drug accumulation or renal effects 2.

Clinical Trial Evidence Shows Kidney Function Improvement

The most compelling evidence comes from a large post-hoc analysis of 6 double-blind randomized controlled trials involving 30,621 patients 3. This study demonstrated that:

  • Atorvastatin improved kidney function over time in a dose-dependent manner
  • Patients on atorvastatin 10 mg showed kidney function improvement (slope: 0.011 [mg/dL]⁻¹/year)
  • Patients on atorvastatin 80 mg showed even greater improvement (slope: 0.014 [mg/dL]⁻¹/year)
  • Placebo patients showed the least improvement (slope: 0.009 [mg/dL]⁻¹/year)
  • The difference between 10 mg and 80 mg doses was statistically significant (P=0.0009)

Additional Supporting Evidence

Multiple randomized controlled trials support atorvastatin's renoprotective effects:

  • A 2007 study in postmenopausal women found that neither moderate (20 mg) nor high-dose (80 mg) atorvastatin altered markers of glomerular or tubular function over 1 year 4
  • A 2010 trial in chronic kidney disease patients showed a 29% slower decline in eGFR with atorvastatin versus placebo 5
  • A 2015 study demonstrated that pre-procedural atorvastatin 80 mg significantly decreased serum creatinine and increased GFR after coronary angiography 6

Important Clinical Context: Contrast-Induced Nephropathy Prevention

Atorvastatin actually protects against kidney injury in high-risk situations. Multiple studies demonstrate that high-dose atorvastatin (80 mg) reduces contrast-induced nephropathy (CIN) in patients undergoing coronary procedures:

  • In diabetic patients with chronic kidney disease undergoing PCI, atorvastatin 80 mg for 48 hours reduced CIN incidence from 20% to 7.7% (P<0.05) 7
  • A 2020 head-to-head comparison showed atorvastatin and rosuvastatin had similar protective effects against AKI in acute coronary syndrome patients 8

Distinguishing Atorvastatin from Fenofibrate

Critical caveat: Do not confuse atorvastatin with fibrates. While atorvastatin improves kidney function, fenofibrate (a fibrate) does increase creatinine and decrease GFR. A 2017 study showed fenofibrate increased serum creatinine by 9.73% while atorvastatin decreased it by 0.89% 9. This distinction is clinically important when choosing lipid-lowering therapy.

Clinical Bottom Line

  • Atorvastatin does not cause renal dysfunction—it improves kidney function over time
  • The effect is dose-dependent, with higher doses (80 mg) showing greater benefit
  • Atorvastatin's minimal renal excretion (<2%) makes it the safest statin choice for patients with kidney concerns 2, 1
  • Regular monitoring of kidney function is not required specifically for atorvastatin-related renal toxicity, though baseline and periodic assessment remains good practice per FDA labeling 1
  • In high-risk situations (contrast exposure, diabetes with CKD), atorvastatin provides renoprotection rather than harm

References

Research

Atorvastatin and prevention of contrast induced nephropathy following coronary angiography.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2015

Research

Effect of Fenofibrate Medication on Renal Function.

Korean journal of family medicine, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.